scispace - formally typeset
Journal ArticleDOI

Irreversible intestinal failure.

TLDR
The causes of irreversible IF are discussed, the specific medico-surgical strategies for prevention and treatment of these conditions at several stages of IF are emphasized and patients may be candidates for intestinal transplantation.
Abstract
Intestinal failure (IF) can be defined as the reduction of functional gut mass below the minimal amount necessary for digestion and absorption adequate to satisfy the nutrient and fluid requirements for maintenance in adults or growth in children. In developed countries, IF mainly includes individuals with the congenital or early onset of conditions requiring protracted or indefinite parenteral nutrition (PN). Short bowel syndrome was the first commonly recognized cause of protracted IF. The normal physiologic process of intestinal adaptation after extensive resection usually allows for recovery of sufficient intestinal function within weeks to months. During this time, patients can be sustained on parenteral nutrition. Only a few children have permanent intestinal insufficiency and life-long dependency on PN. Non-transplant surgery including small bowel tapering and lengthening may allow weaning from PN in some cases. Hormonal therapy with recombinant human growth hormone has produced poor results while therapy with glucagon-like peptide-2 holds promise. Congenital diseases of enterocyte development such as microvillus inclusion disease or intestinal epithelial dysplasia cause permanent IF for which no curative medical treatment is currently available. Severe and extensive motility disorders such as total or subtotal intestinal agangli-onosis (long segment Hirschsprung disease) or chronic intestinal pseudo-obstruction syndrome may also cause permanent IF. PN and home-PN remain are the mainstays of therapy regardless of the cause of IF. Some patients develop complications while receiving long-term PN for IF especially catheter related complications (thrombosis, sepsis) and liver disease. These patients may be candidates for intestinal transplantation. This review discusses the causes of irreversible IF and emphasizes the specific medico-surgical strategies for prevention and treatment of these conditions at several stages of IF.

read more

Citations
More filters
Journal ArticleDOI

1. Guidelines on Paediatric Parenteral Nutrition of the European Society of Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN) and the European Society for Clinical Nutrition and Metabolism (ESPEN), Supported by the European Society of Paediatric Research (ESPR).

TL;DR: These Guidelines for Paediatric Parenteral Nutrition have been developed as a mutual project of the European Society for paediatric Gastroenterology, Hepatology and Nutrition and the European society for Clinical Nutrition and Metabolism.
Journal ArticleDOI

2003 report of the intestine transplant registry: a new era has dawned.

TL;DR: Transplantation is an effective therapy for the treatment of patients with end-stage intestine failure who cannot tolerate parenteral nutrition and with newer immune suppressive protocols, 1-year graft and patient survival rates approach the results of liver transplantation.
Journal ArticleDOI

ESPEN Guidelines on Parenteral Nutrition: home parenteral nutrition (HPN) in adult patients.

TL;DR: The purpose of these guidelines is to highlight areas of good practice and promote the use of standardized treatment protocols between centers, and may serve as a framework for development of policies and procedures.
References
More filters
Journal ArticleDOI

Medium-chain triglycerides: an update

TL;DR: A review of the literature on the medical and nutritional use of medium-chain triglycerides (MCTs) since 1970 is presented with additional discussions on the various modifications and applications of the MCTs in the synthesis of certain structured lipids.
Journal ArticleDOI

Biological actions and therapeutic potential of the glucagon-like peptides.

TL;DR: Inhibitors of DP IV activity, or DP IV-resistant glucagon-like peptide analogues, may be alternative therapeutic approaches for treatment of human diseases.
Journal ArticleDOI

Glucagon-like peptide 2 improves nutrient absorption and nutritional status in short-bowel patients with no colon

TL;DR: Treatment with GLP-2 improves intestinal absorption and nutritional status in short-bowel patients with impaired postprandial GLp-2 secretion in whom the terminal ileum and the colon have been resected.
Journal ArticleDOI

Current use and clinical outcome of home parenteral and enteral nutrition therapies in the United States.

TL;DR: Predicted quality survival at home for several months, rather than a specific diagnosis, seems to be the soundest justification for HPEN and its role in terminal conditions and patients without primary gastrointestinal diseases needs further evaluations.
Related Papers (5)